Metabolic & Incretin Research blend
Tirzepatide + Retatrutide TR+RT 45
Dual + triple incretin blend
Research blend of tirzepatide, a GIP and GLP-1 dual agonist, and retatrutide, which adds glucagon receptor activity.
Evidence level. Little or no public data, or the exact identity is still being confirmed. For a blend, the rating covers the combination itself; each component has its own profile. About the badges
- Class
- Dual + triple incretin blend
- Category
- Metabolic & Incretin
- Type
- Research blend
- Abbreviation
- TR+RT 45
- Development and regulatory status
- Combination not approved; tirzepatide approved alone, retatrutide investigational
Blend composition
Tirzepatide 30 mg + Retatrutide 15 mg
Each component is profiled separately in the catalogue: Tirzepatide, Retatrutide.
What researchers study
A research blend of tirzepatide, a GIP/GLP-1 dual agonist, and retatrutide, which adds glucagon-receptor activity to GIP and GLP-1 agonism. The pairing allows comparison of dual and triple incretin-family signalling.
Research areas
- Comparative incretin pharmacology across dual and triple agonists
- Glucagon-receptor contribution to energy expenditure
- GIP and GLP-1 receptor signalling in cells
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- literature check
No published studies of this specific tirzepatide plus retatrutide combination were identified
- phase 3 trial
Tirzepatide alone: mean weight change at 72 weeks ranged from -15% to -20.9% across dose groups versus -3.1% with placebo in 2,539 adults
- phase 2 trial
Retatrutide alone: mean weight change at 48 weeks was -24.2% in the highest-dose group versus -2.1% with placebo, in 338 adults
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Tirzepatidedual GIP/GLP-1 agonist, a component of this blend
- Retatrutidetriple GIP/GLP-1/glucagon agonist, a component of this blend
